EP1569684A4 - Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires - Google Patents

Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires

Info

Publication number
EP1569684A4
EP1569684A4 EP03789973A EP03789973A EP1569684A4 EP 1569684 A4 EP1569684 A4 EP 1569684A4 EP 03789973 A EP03789973 A EP 03789973A EP 03789973 A EP03789973 A EP 03789973A EP 1569684 A4 EP1569684 A4 EP 1569684A4
Authority
EP
European Patent Office
Prior art keywords
hmgb
fragments
inflammatory agents
inflammatory
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03789973A
Other languages
German (de)
English (en)
Other versions
EP1569684A2 (fr
Inventor
Walter Newman
Theresa L O'keefe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi USA Inc
Original Assignee
Critical Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Therapeutics Inc filed Critical Critical Therapeutics Inc
Publication of EP1569684A2 publication Critical patent/EP1569684A2/fr
Publication of EP1569684A4 publication Critical patent/EP1569684A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
EP03789973A 2002-11-20 2003-11-20 Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires Withdrawn EP1569684A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US42784602P 2002-11-20 2002-11-20
US42784102P 2002-11-20 2002-11-20
US427846P 2002-11-20
US427841P 2002-11-20
PCT/US2003/037507 WO2004046345A2 (fr) 2002-11-20 2003-11-20 Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires

Publications (2)

Publication Number Publication Date
EP1569684A2 EP1569684A2 (fr) 2005-09-07
EP1569684A4 true EP1569684A4 (fr) 2006-08-02

Family

ID=32329191

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03789973A Withdrawn EP1569684A4 (fr) 2002-11-20 2003-11-20 Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires

Country Status (6)

Country Link
EP (1) EP1569684A4 (fr)
JP (1) JP2006510619A (fr)
AU (1) AU2003294488B2 (fr)
CA (1) CA2506328A1 (fr)
NZ (1) NZ540067A (fr)
WO (1) WO2004046345A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
WO2005025604A2 (fr) * 2003-09-10 2005-03-24 The General Hospital Corporation Utilisation de hmgb et fragments de hmgb pour faire diminuer la reponse immunitaire specifique
CA2538763C (fr) 2003-09-11 2015-05-05 Critical Therapeutics, Inc. Anticorps monoclonaux diriges contre hmgb1
US20080305073A1 (en) * 2004-07-02 2008-12-11 Barone Domenico G Therapeutic Agents for the Treatment of Hmgb1-Related Pathologies
WO2006012373A2 (fr) * 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Polytherapies hmgb
MX2007002557A (es) * 2004-09-03 2007-10-10 Creabilis Therapeutics Spa Uso de polipeptidos obtenidos a traves de mutaciones sistematicas de aminoacidos unicos de bloque-a humano y no humano de hmgb1 para prevenir y/o antagonizar las patologias inducidas por hmgb1.
WO2007001422A2 (fr) * 2004-10-22 2007-01-04 Medimmune, Inc. Anticorps d'affinité élevée contre la hmgb1 et procédés d'utilisation
EP2364998A1 (fr) * 2005-06-16 2011-09-14 The Feinstein Institute for Medical Research Anticorps contre le HMGB1 et fragments associés
EP1909834A2 (fr) * 2005-07-18 2008-04-16 Critical Therapeutics, Inc. Utilisation d'antagonistes hmgb1 pour traiter des etats inflammatoires de la peau
WO2007031100A1 (fr) * 2005-09-14 2007-03-22 Ostini, Marco Immunothérapie active pour inflammation systémique potentiellement mortelle
AU2006312847A1 (en) * 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting HMGB1
US8546547B2 (en) * 2006-09-15 2013-10-01 Creabilis Therapeutics S.P.A. Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
US8604178B2 (en) 2006-09-18 2013-12-10 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
JP5225109B2 (ja) 2007-02-15 2013-07-03 国立大学法人 熊本大学 ヒトｈｍｇｂ−１に特異的に結合する抗体を有効成分として含有する治療剤
CN102083962B (zh) 2008-04-30 2013-03-27 吉诺米克斯股份有限公司 生物体内功能性细胞的高效采集方法
CN102711777B (zh) 2009-10-28 2015-04-15 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
DK2525817T3 (en) 2010-01-21 2017-10-02 Univ Arkansas Vaccine vectors and methods for enhancing immune responses
JP5746333B2 (ja) 2010-06-09 2015-07-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー カンピロバクター感染を減少させるワクチン及び方法
EP3358011B1 (fr) 2011-04-26 2020-03-04 StemRIM Inc. Peptide permettant d'induire la régénération d'un tissu et son utilisation
DK2913059T3 (en) * 2012-10-25 2018-06-25 Genomix Co Ltd Hitherto UNKNOWN PROCEDURE FOR TREATMENT OF SPINE INJURY USING HMGB1 FRAGMENT
BR112015009037A2 (pt) 2012-10-25 2017-11-14 Genomix Co Ltd composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
KR20150134319A (ko) 2013-01-28 2015-12-01 에베크 인코포레이티드 인간화 항 hmgb1 항체 또는 그의 항원 결합성 단편
PT2956165T (pt) 2013-02-14 2019-11-29 Texas A & M Univ Sys Composições e métodos de potenciação das respostas imunitárias frente a eimeria ou limitação de uma infeção por eimeria
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
EP3452069A4 (fr) 2016-05-03 2020-02-12 The Board of Trustees of the University of Arkansas Vecteur vaccinal de levure comprenant des polypeptides immunostimulants et antigéniques et ses procédés d'utilisation
WO2018139562A1 (fr) 2017-01-27 2018-08-02 株式会社ジェノミックス Agent thérapeutique pour les cardiomyopathies, l'infarctus du myocarde ancien et l'insuffisance cardiaque chronique
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
EP3750553A4 (fr) * 2018-02-08 2022-01-12 Stemrim Inc. Agent thérapeutique contre le psoriasis
CN112823038A (zh) * 2018-10-05 2021-05-18 国家儿童医院研究所 用于移除生物膜的hmgb1蛋白衍生物
CN111743890A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 水绫霉素或其衍生物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (fr) * 1999-02-26 2000-09-06 Genset Marqueurs de séquence exprimées et protéines humaines codées

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1033401A2 (fr) * 1999-02-26 2000-09-06 Genset Marqueurs de séquence exprimées et protéines humaines codées

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DAILEY LISA ET AL: "Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 186, no. 3, March 2001 (2001-03-01), pages 315 - 328, XP002373261, ISSN: 0021-9541 *
DATABASE Geneseq [online] 6 October 2000 (2000-10-06), "Human secreted protein, SEQ ID NO: 7904.", XP002373264, retrieved from EBI accession no. GSN:AAG03823 Database accession no. AAG03823 *
ROGALLA P ET AL: "Mapping and molecular characterization of five HMG1-related DNA sequences", CYTOGENETICS AND CELL GENETICS, vol. 83, no. 1-2, 1998, pages 124 - 129, XP009063822, ISSN: 0301-0171 *
YANG HUAN ET AL: "Reversing established sepsis with antagonists of endogenous high-mobility group box 1.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 1, 6 January 2004 (2004-01-06), pages 296 - 301, XP002373262, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2003294488B2 (en) 2007-05-24
AU2003294488A1 (en) 2004-06-15
NZ540067A (en) 2007-05-31
JP2006510619A (ja) 2006-03-30
EP1569684A2 (fr) 2005-09-07
WO2004046345A2 (fr) 2004-06-03
WO2004046345A3 (fr) 2004-12-02
CA2506328A1 (fr) 2004-06-03

Similar Documents

Publication Publication Date Title
EP1569684A4 (fr) Utilisation de fragments hmgb en tant qu'agents anti-inflammatoires
IL158643A0 (en) Use of hmg fragments as anti-inflammatory agents
AU2003255482A1 (en) Use of 4 amino-quinazolines as anti cancer agents
AU2003259735A8 (en) Small-mer compositions and methods of use
AU2003285091A1 (en) Interferon antagonists useful for the treatment of interferon related diseases
PL375784A1 (en) Use of erythopoietin
AU2003299441A8 (en) Nf-hev compositions and methods of use
AU2003258662A1 (en) Use of 4-amino-quinazolines as anti cancer agents
AU2003279841A1 (en) Uses of human zven antagonists
AU2003278157A1 (en) Novel phenylethanolamine derivatives and the use of the same as beta-3-agonists
IL165839A0 (en) Compounds useful for the treatment of cancer compositions thereof and methods therewith
GB2392618B (en) Compositions for therapeutic use
PL372655A1 (en) Compositions of pentafluoropropane
GB0218798D0 (en) Improvements to determination of ovulation
PL371427A1 (en) New uses of substituted aminoalkanephosphonic acids
AU2003282510A8 (en) Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents
EP1534293A4 (fr) Compositions anti-inflammatoires et procedes d'utilisation
AU2003270202A8 (en) Pharmaceutical compositions useful for the treatment of cancers
AU2003298725A8 (en) Preparation of metallotexaphyrins
AU2003240174A8 (en) Compositions for the treatment of edematous-firbrosclerotic panniculopathy
AU2003252185A8 (en) Topical composition for the treatment of scar tissue
EP1546326A4 (fr) Nouvelles compositions et methodes destinees au traitement du psoriasis
AU2003227519A1 (en) The use of milnacipran for the treatment of tension-type headache
AU2003279282A8 (en) Methods and compositions for the treament of cancer
HUP0203929D0 (en) New use of substituted alkyl-piridazinone derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060630

RIN1 Information on inventor provided before grant (corrected)

Inventor name: O'KEEFE, THERESA, L.

Inventor name: NEWMAN, WALTER

17Q First examination report despatched

Effective date: 20080818

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081230